Several other research firms have also issued reports on ORIC. Zacks Investment Research raised ORIC Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, November 10th. HC Wainwright reaffirmed a buy rating on shares of ORIC Pharmaceuticals in a report on Monday, November 9th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $42.75.
Shares of ORIC Pharmaceuticals stock opened at $31.26 on Tuesday. ORIC Pharmaceuticals has a 52 week low of $18.60 and a 52 week high of $40.81. The business has a 50 day moving average price of $34.78 and a 200-day moving average price of $26.98.
ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Thursday, November 5th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.45). On average, equities research analysts predict that ORIC Pharmaceuticals will post -2.11 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jennison Associates LLC raised its position in shares of ORIC Pharmaceuticals by 0.4% in the third quarter. Jennison Associates LLC now owns 150,601 shares of the company’s stock worth $3,767,000 after buying an additional 543 shares in the last quarter. California Public Employees Retirement System raised its position in shares of ORIC Pharmaceuticals by 4.2% in the third quarter. California Public Employees Retirement System now owns 20,049 shares of the company’s stock worth $501,000 after buying an additional 800 shares in the last quarter. M&T Bank Corp raised its position in ORIC Pharmaceuticals by 28.4% during the third quarter. M&T Bank Corp now owns 8,047 shares of the company’s stock valued at $201,000 after purchasing an additional 1,782 shares in the last quarter. UBS Group AG purchased a new stake in ORIC Pharmaceuticals during the second quarter valued at about $96,000. Finally, American International Group Inc. purchased a new position in shares of ORIC Pharmaceuticals in the second quarter worth about $180,000. 71.79% of the stock is owned by institutional investors and hedge funds.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors.
Featured Article: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for ORIC Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.